Retrospective evaluation of the safety and tolerability of pimobendan in cats with obstructive vs nonobstructive cardiomyopathy
JOURNAL OF VETERINARY INTERNAL MEDICINE, 34(6), 2211–2222.
author keywords: cardiac; cardiomyopathy; feline; hypertrophic; positive inotrope
MeSH headings : Animals; Cardiomyopathies / drug therapy; Cardiomyopathies / veterinary; Cardiotonic Agents / adverse effects; Cat Diseases / drug therapy; Cats; Heart Failure / drug therapy; Heart Failure / veterinary; Pyridazines / adverse effects; Retrospective Studies
TL;DR:
Pimobendan is well tolerated in cats with cardiomyopathy and CHF, regardless of the presence of OTO, and was discontinued due to adverse effects in 4/260 cats.
(via
Semantic Scholar)
UN Sustainable Development Goal Categories